Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aileron Therapeutics Inc ALRN

Healthcare Biotechnology
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib... see more

Recent & Breaking News (NDAQ:ALRN)

Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements

GlobeNewswire November 30, 2022

Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split

GlobeNewswire November 10, 2022

Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

GlobeNewswire November 1, 2022

Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference

GlobeNewswire October 26, 2022

Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022

GlobeNewswire September 30, 2022

Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference

GlobeNewswire September 22, 2022

Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 6, 2022

Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

GlobeNewswire August 15, 2022

Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer

GlobeNewswire August 1, 2022

Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022

GlobeNewswire July 8, 2022

Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

GlobeNewswire June 29, 2022

Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer

GlobeNewswire May 19, 2022

Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire May 17, 2022

Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022

GlobeNewswire May 13, 2022

Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual Meeting

GlobeNewswire May 10, 2022

Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

GlobeNewswire May 5, 2022

Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical Operations

GlobeNewswire April 21, 2022

Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

GlobeNewswire March 28, 2022

Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference

GlobeNewswire March 22, 2022

Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones

GlobeNewswire January 5, 2022